Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator

PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Yonsei Med J
Autors principals: Kwon, Hyeok Chan, Kim, Minyoung Kevin, Song, Jason Jungsik, Park, Yong-Beom, Lee, Sang-Won
Format: Artigo
Idioma:Inglês
Publicat: Yonsei University College of Medicine 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393299/
https://ncbi.nlm.nih.gov/pubmed/32734735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.8.712
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars